Abstract:Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating disease with high morbidity and mortality. Cerebral vasospasm, which develops in 3–12 days after aneurysm rupture, has traditionally been considered the major cause of poor outcome postaSAH. However, clinical trials demonstrated that antivasospastic drugs, such as clazosentan, failed to improve the neurofunctional outcomes of patients with aSAH [1], indicating that a complex etiology is involved in the pathogenesis of delayed ischemic neurological deficits (DINDs). Therefore, further elucidation of the pathogenic mechanisms and development of novel effective drugs is of great importance for aSAH treatment. Recently, extensive research has focused on early brain injury (EBI), which occurs within the first 72 h after aSAH. In addition to mechanical damage, hypoxia, and molecular alterations (e.g., NO pathway dysfunction, oxidative stress), EBI can result from inflammation. Importantly, cerebral edema is a major risk factor for early death and bad outcome following aSAH. Additionally, disruption of blood brain barrier (BBB) and inflammation exacerbates the development of EBI by promoting cerebral edema formation. Matrix metalloproteinase 9 (MMP-9) is involved in the degradation of tight junction proteins and microvascular basal lamina proteins, leading to BBB breakdown and brain edema. Thus, suppressing the inflammatory response and MMP-9 activity is vital for the alleviation of EBI in aSAH. Resveratrol (RVS) (3,4′,5-trihydroxystilbene), a natural polyphenol, exerts protective effects against multiple neurological injuries in animal models such as stroke, traumatic brain injury, and spinal cord injury [2–4]. The beneficial effects of resveratrol in central nervous system injuries are associated with its anti-oxidant, antiinflammatory, and antiapoptotic properties [3]. In particular, the inhibitory action of resveratrol on NF-jB has been demonstrated in experimental diabetic neuropathy [5]. NF-jB inhibition can result in downregulation of MMP-9 expression and suppression of the inflammatory response post-SAH [6]. However, although the antivasospastic effect of resveratrol in experimental SAH has been reported [7], no experimental studies to date have focused on the effect of resveratrol on BBB disruption and inflammation after SAH. In our study, we aimed to evaluate whether resveratrol could improve neurological outcomes through inhibition of the NF-jB-dependent inflammatory/MMP-9 pathway after SAH. In this study, aSAH model was induced using a perforation method in sixty Sprague–Dawley rats. Then, resveratrol (30 mL/kg) or normal saline (30 mL/kg) was administered intraperitoneally immediately and again at 6 h after SAH. We found that resveratrol reduced brain edema and promoted functional recovery by preventing BBB disruption after SAH. Further, postSAH resveratrol treatment inhibited the activation of NF-jB, which leads to the downregulation of MMP-9 expression and inhibition of inflammation, contributing to maintenance of BBB integrity. The BBB is a highly specialized structure of the brain microvascular system, and the integrity of BBB is essential for maintaining cerebral microenvironment homeostasis and neural function. Matrix metalloproteases (MMPs), a family of zinc endopeptidases, can degrade interendothelial tight junction proteins and basal lamina proteins of the BBB. Accumulating evidence has demonstrated that MMP-9 participates in the early BBB disruption and cerebral edema formation after aSAH [8]. Increased activity of NFjB has also been observed in both early and late stages of SAH. In

Astrocytic NDRG2-PPM1A interaction exacerbates blood-brain barrier disruption after subarachnoid hemorrhage

PDGFR-β modulates vascular smooth muscle cell phenotype via IRF-9/SIRT-1/NF-κB pathway in subarachnoid hemorrhage rats.

Mesencephalic astrocyte-derived neurotrophic factor affords neuroprotection to early brain injury induced by subarachnoid hemorrhage via activating Akt-dependent prosurvival pathway and defending blood-brain barrier integrity.

Potential Contribution of Hypoxia-Inducible Factor-1α, Aquaporin-4, and Matrix Metalloproteinase-9 to Blood–Brain Barrier Disruption and Brain Edema after Experimental Subarachnoid Hemorrhage

PARP Inhibition Attenuates Early Brain Injury Through NF-κB/MMP-9 Pathway in a Rat Model of Subarachnoid Hemorrhage.

Peroxisome Proliferator–Activated Receptor Β/δ Alleviates Early Brain Injury after Subarachnoid Hemorrhage in Rats

The role of p53 in brain edema after 24 h of experimental subarachnoid hemorrhage in a rat model

BMSCs Regulate Astrocytes through TSG-6 to Protect the Blood-Brain Barrier after Subarachnoid Hemorrhage

Astaxanthin Reduces Matrix Metalloproteinase-9 Expression and Activity in the Brain after Experimental Subarachnoid Hemorrhage in Rats

Hemorrhagic stroke-induced subtype of inflammatory reactive astrocytes disrupts blood-brain barrier

Blood-brain barrier disruption following subarchnoid hemorrhage may be faciliated through PUMA induction of endothelial cell apoptosis from the endoplasmic reticulum.

PEDF-34 attenuates neurological deficit and suppresses astrocyte-dependent neuroinflammation by modulating astrocyte polarization via 67LR/JNK/STAT1 signaling pathway after subarachnoid hemorrhage in rats

Activation of RARα Receptor Attenuates Neuroinflammation After SAH via Promoting M1-to-M2 Phenotypic Polarization of Microglia and Regulating Mafb/Msr1/PI3K-Akt/NF-κB Pathway

EphA4/EphrinB2 signaling mediates pericyte-induced transient glia limitans formation as a secondary protective barrier after subarachnoid hemorrhage in mice

Resveratrol Attenuates Early Brain Injury after Subarachnoid Hemorrhage Through Inhibition of NF‐κB‐Dependent Inflammatory/MMP‐9 Pathway

Methylated MFGE8 Promotes Early Brain Injury After Subarachnoid Hemorrhage and Inhibiting Autophagy of Nerve Cell

Inhibition of HIF-1α Reduced Blood Brain Barrier Damage by Regulating MMP-2 and VEGF During Acute Cerebral Ischemia.

Aggf1 attenuates neuroinflammation and BBB disruption via PI3K/Akt/NF-κB pathway after subarachnoid hemorrhage in rats

GPR30 alleviated subarachnoid hemorrhage-induced blood-brain barrier dysfunction by activating the PI3K/Akt and Nrf2/HO-1 pathways

Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage

Crosstalk between soluble PDGF-BB and PDGFRβ promotes astrocytic activation and synaptic recovery in the hippocampus after subarachnoid hemorrhage.